Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

NCT01431638 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

397

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Gouty Arthritis

Interventions

DRUG: Canakinumab 150mg in prefilled syringe

Sponsor

Novartis Pharmaceuticals